EUVIMEDEUVIMED entdecken
Crossref

D-peptide-nanodrug conjugates synergize VISTA blockade and innate activation for cancer immunotherapy

Beibei Li, Qingchao Wang, Xiaoxi Wang, Peixin Chen, Xinyu Zi, Yanping Ma, Qiaoya Xuan, Ying Cheng, Shihan Zhang, Hanke Feng, Wenjie Zhai, Yahong Wu und 4 weitere

Journal of Controlled Release · 2026-10 · 398 · 115201

DOI: 10.1016/j.jconrel.2026.115201 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2026-10. Verfasst von Beibei Li und 15 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China. Hauptthemen laut MEDLINE: Imidazoles, Nanoparticles, Peptides, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Henan Province Natural Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Effective cancer immunotherapy is often hindered by V-domain Ig suppressor of T cell activation (VISTA) signaling and myeloid-derived suppressor cells (MDSCs) within tumor microenvironment (TME). Here, we report D-peptide-nanodrug conjugates that synergize VISTA blockade and innate activation to overcome these constraints. We developed Reorpn7, a proteolytically stable D-peptide VISTA inhibitor with high binding affinity and in vitro serum stability. This inhibitor was co-loaded with a toll-like receptor 7/8 (TLR7/8) agonist (R848) into an matrix metalloproteinase-2 (MMP-2) responsive poly lactic-co-glycolic acid (PLGA) nanoplatform (r7PL-PLGA@R848). Upon enrichment in the TME, MMP-2 responsive cleavage enables the precise release of the VISTA-targeting peptide Reorpn7 and the TLR7/8 agonist R848, thereby achieving synergistic therapeutic effect of VISTA blockade and innate immune activation. In MC38 tumor models, this nanosystem significantly increased intratumoral CD8+ T cell infiltration and achieved robust antitumor efficacy without obvious systemic toxicity. Mechanistically, the platform reshaped the TME from an inhibitory milieu into an immunosupportive one by coordinating checkpoint blockade, myeloid reprogramming, and T cell recruitment. This stimuli-responsive paradigm offers a translatable strategy to overcome immune checkpoint blockade resistance in challenging malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImidazolesNanoparticlesPeptidesNeoplasmsAnimalsImmunotherapyToll-Like Receptor AgonistsMice, Inbred C57BLMiceImmunity, InnateTumor MicroenvironmentToll-Like Receptor 7HumansCell Line, TumorToll-Like Receptor 8FemalePolylactic Acid-Polyglycolic Acid CopolymerMembrane Proteins

Stichwörter der Autor:innen

Cancer immunotherapyImmune checkpointPeptideTLR7/8 agonistVISTA

Substanzen

Toll-Like Receptor AgonistsresiquimodImidazolesVsir protein, mouseToll-Like Receptor 7PeptidesToll-Like Receptor 8Polylactic Acid-Polyglycolic Acid CopolymerMembrane Proteins

Autor:innen und Institutionen

  • School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China.
  • School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China; State Key Laboratory of Antiviral Drugs, College of Chemistry, Pingyuan Laboratory, Zhengzhou University, Zhengzhou 450001, China; State Key Labora…
  • School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China; Henan Key Laboratory of Bioactive Macromolecules, Zhengzhou University, Zhengzhou 450001, China.
  • Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450051, China.
  • School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China. Electronic address: zhouxw@zzu.edu.cn.
  • State Key Laboratory of Antiviral Drugs, College of Chemistry, Pingyuan Laboratory, Zhengzhou University, Zhengzhou 450001, China; State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal…

Förderung

  • Henan Province Natural Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Li, B., Wang, Q., Wang, X., Chen, P., Zi, X., Ma, Y., Xuan, Q., Cheng, Y., Zhang, S., Feng, H., Zhai, W., Wu, Y., Zhao, Y., Zhou, X., Niu, X., & Zhao, W. (2026). D-peptide-nanodrug conjugates synergize VISTA blockade and innate activation for cancer immunotherapy. Journal of Controlled Release, 398, 115201. https://doi.org/10.1016/j.jconrel.2026.115201

Vancouver

Li B, Wang Q, Wang X, Chen P, Zi X, Ma Y, et al. D-peptide-nanodrug conjugates synergize VISTA blockade and innate activation for cancer immunotherapy. Journal of Controlled Release. 2026;398:115201. doi:10.1016/j.jconrel.2026.115201

BibTeX
@article{Li2026,
  author = {Li, Beibei and Wang, Qingchao and Wang, Xiaoxi and Chen, Peixin and Zi, Xinyu and Ma, Yanping and Xuan, Qiaoya and Cheng, Ying and Zhang, Shihan and Feng, Hanke and Zhai, Wenjie and Wu, Yahong and Zhao, Yumiao and Zhou, Xiaowen and Niu, Xiaoshuang and Zhao, Wenshan},
  title = {D-peptide-nanodrug conjugates synergize VISTA blockade and innate activation for cancer immunotherapy},
  journal = {Journal of Controlled Release},
  year = {2026},
  volume = {398},
  pages = {115201},
  doi = {10.1016/j.jconrel.2026.115201}
}
Kostenlos starten →